DK3074036T3 - Fremstilling af antistoffer ud fra CHO-cellekulturer til konjugation. - Google Patents

Fremstilling af antistoffer ud fra CHO-cellekulturer til konjugation. Download PDF

Info

Publication number
DK3074036T3
DK3074036T3 DK14863650T DK14863650T DK3074036T3 DK 3074036 T3 DK3074036 T3 DK 3074036T3 DK 14863650 T DK14863650 T DK 14863650T DK 14863650 T DK14863650 T DK 14863650T DK 3074036 T3 DK3074036 T3 DK 3074036T3
Authority
DK
Denmark
Prior art keywords
conjugation
antibodies
preparation
cell cultures
cho cell
Prior art date
Application number
DK14863650T
Other languages
English (en)
Inventor
Bradley Hayes
Kevin Beam
Damon Meyer
Robert Lyon
John Valliere-Douglass
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Application granted granted Critical
Publication of DK3074036T3 publication Critical patent/DK3074036T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/34Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0681Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y108/00Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/03Oxidoreductases acting on sulfur groups as donors (1.8) with oxygen as acceptor (1.8.3)
    • C12Y108/03002Thiol oxidase (1.8.3.2)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0051Oxidoreductases (1.) acting on a sulfur group of donors (1.8)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK14863650T 2013-11-25 2014-11-21 Fremstilling af antistoffer ud fra CHO-cellekulturer til konjugation. DK3074036T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908568P 2013-11-25 2013-11-25
PCT/US2014/066889 WO2015077605A1 (en) 2013-11-25 2014-11-21 Preparing antibodies from cho cell cultures for conjugation

Publications (1)

Publication Number Publication Date
DK3074036T3 true DK3074036T3 (da) 2019-11-18

Family

ID=53180202

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14863650T DK3074036T3 (da) 2013-11-25 2014-11-21 Fremstilling af antistoffer ud fra CHO-cellekulturer til konjugation.

Country Status (14)

Country Link
US (2) US10457976B2 (da)
EP (1) EP3074036B1 (da)
JP (2) JP6529188B2 (da)
KR (1) KR102306493B1 (da)
CN (1) CN105979963B (da)
AU (1) AU2014352824B2 (da)
CA (1) CA2928238C (da)
DK (1) DK3074036T3 (da)
EA (1) EA034123B1 (da)
ES (1) ES2753269T3 (da)
IL (1) IL245190B (da)
MX (1) MX2016006551A (da)
SG (2) SG11201602995VA (da)
WO (1) WO2015077605A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150083689A (ko) * 2014-01-10 2015-07-20 삼성전자주식회사 항 c-Met 항체 정제 방법
WO2016121701A1 (ja) 2015-01-26 2016-08-04 株式会社カネカ 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス
JP6663360B2 (ja) 2015-01-26 2020-03-11 株式会社カネカ 変異型免疫グロブリンκ鎖可変領域結合性ペプチド
EP3394082B1 (en) * 2015-12-21 2020-08-12 Pfizer Inc Purification of antibody drug conjugates using a sodium phosphate gradient
WO2017195638A1 (ja) * 2016-05-09 2017-11-16 株式会社カネカ 抗体またはκ鎖可変領域含有抗体断片の精製方法
WO2018116269A1 (en) * 2016-12-22 2018-06-28 Lupin Limited Depth filtration of a protein
KR20220002581A (ko) * 2019-05-03 2022-01-06 제넨테크, 인크. 정제 플랫폼으로부터 수득된 조성물의 효소적 가수분해 활성 속도를 감소시키는 방법
KR20220041915A (ko) 2019-08-06 2022-04-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 바이오제약 조성물 및 관련 방법
TW202323822A (zh) 2021-08-03 2023-06-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 生藥組合物及穩定同位素標記肽之圖譜定位方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ES2195036T3 (es) 1995-12-22 2003-12-01 Bristol Myers Squibb Co Conectores de hidrazona ramificados.
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
JP4741838B2 (ja) 2002-07-31 2011-08-10 シアトル ジェネティクス,インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
CA2841741C (en) 2003-11-06 2020-01-07 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2007109163A2 (en) * 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
AU2008318865B2 (en) 2007-10-30 2012-06-28 Genentech, Inc. Antibody purification by cation exchange chromatography
KR101238061B1 (ko) 2009-03-31 2013-02-27 한화케미칼 주식회사 Vcam-1에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
CN107019804A (zh) 2010-04-15 2017-08-08 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
EP3483184A1 (en) 2012-03-07 2019-05-15 Yeda Research and Development Co. Ltd Compositions for inhibition of quiescinsulfhydryl oxidase (qsox1) and uses of same
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer

Also Published As

Publication number Publication date
CA2928238C (en) 2021-08-17
CA2928238A1 (en) 2015-05-28
AU2014352824B2 (en) 2019-07-18
US20170159099A1 (en) 2017-06-08
EA201691094A1 (ru) 2016-09-30
EP3074036B1 (en) 2019-09-18
JP2016539130A (ja) 2016-12-15
JP2019048888A (ja) 2019-03-28
US10457976B2 (en) 2019-10-29
MX2016006551A (es) 2016-09-06
JP6529188B2 (ja) 2019-06-12
SG10201710475WA (en) 2018-01-30
WO2015077605A1 (en) 2015-05-28
CN105979963A (zh) 2016-09-28
EP3074036A4 (en) 2017-07-26
AU2014352824A1 (en) 2016-05-12
ES2753269T3 (es) 2020-04-07
EP3074036A1 (en) 2016-10-05
CN105979963B (zh) 2020-03-03
IL245190A0 (en) 2016-06-30
KR102306493B1 (ko) 2021-09-28
SG11201602995VA (en) 2016-05-30
KR20160089454A (ko) 2016-07-27
EA034123B1 (ru) 2019-12-30
IL245190B (en) 2021-02-28
US20200063180A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
DK3074036T3 (da) Fremstilling af antistoffer ud fra CHO-cellekulturer til konjugation.
DK3006568T3 (da) Fremgangsmåde til fremstilling af tagatose
DK3926051T3 (da) Fremgangsmåder til høst af pattedyrecellekulturer
CL2016001190A1 (es) Cultivo de células de mamífero.
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK2847231T3 (da) Multispecifikke monoklonale antistoffer
DK3611262T3 (da) Fremgangsmåder til sekvensering af immunrepertoire
DK3083694T3 (da) Caniniserede, murine anti-canin-pd-1-antistoffer
DK2857419T3 (da) Antigen-bindende molekyle til eliminering af aggregerede antigener
DK2934584T3 (da) Anti-gdf15-antistoffer
DK2841623T3 (da) Fremgangsmåder til fremstilling af lithiumhydroxid
DK2972353T3 (da) Forbedrede fremgangsmåder til udførelse af multipleksanalyser
BR112015008635A2 (pt) anticorpos anti-hiv amplamente neutralizantes.
DK3156416T3 (da) Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer
DK3080304T3 (da) Fremgangsmåde til fremstillingen af sukre fra biomasse
DK2940051T3 (da) Fremgangsmåde til fremstilling af biomassebaseret polymeremulsion
DK2850101T3 (da) Anti-FcRn-antistoffer
DK2846632T3 (da) Lukkede systemer til tilvejebringelse af reproduktivt habitat for hermetia illucens
DK2817333T3 (da) Bispecifikke, asymmetriske igg4-antistoffer
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3275896T3 (da) Fremgangsmåde til at opnå antistoffer
UY34582A (es) Anticuerpos anti-cxcr3
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer
DK2931313T3 (da) Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer
BR112015023620A2 (pt) preparação de malto-oligossacarídeos.